1. Home
  2. KRYS vs GATX Comparison

KRYS vs GATX Comparison

Compare KRYS & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$347.90

Market Cap

10.3B

Sector

Health Care

ML Signal

HOLD

Logo GATX Corporation

GATX

GATX Corporation

HOLD

Current Price

$179.60

Market Cap

6.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRYS
GATX
Founded
2015
1898
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
6.1B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
KRYS
GATX
Price
$347.90
$179.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
2
Target Price
$297.60
$215.50
AVG Volume (30 Days)
292.9K
202.2K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
1.36%
EPS Growth
128.00
17.22
EPS
1.83
2.35
Revenue
$389,130,000.00
$1,740,400,000.00
Revenue This Year
$38.74
$42.21
Revenue Next Year
$32.53
$3.35
P/E Ratio
$185.91
$75.73
Revenue Growth
33.94
9.77
52 Week Low
$130.50
$148.20
52 Week High
$356.50
$205.56

Technical Indicators

Market Signals
Indicator
KRYS
GATX
Relative Strength Index (RSI) 70.03 54.44
Support Level $253.89 $166.31
Resistance Level N/A $186.61
Average True Range (ATR) 12.45 3.88
MACD 2.83 1.34
Stochastic Oscillator 86.45 83.57

Price Performance

Historical Comparison
KRYS
GATX

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

About GATX GATX Corporation

GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.

Share on Social Networks: